No, the demand for onko sure was about $300,000 per year. And Radient spent $10 million per year in operations. That is why there is no takeover or merger. nobody wants to take over THAT kind of underperformance. Every biotech CEO says the cancer industry is worth billions per year. Every intelligent investors knows it's just hype.